

# Gerhardt Attard

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4699338/publications.pdf>

Version: 2024-02-01

220  
papers

25,631  
citations

10389

72  
h-index

6654

156  
g-index

227  
all docs

227  
docs citations

227  
times ranked

20980  
citing authors

#	ARTICLE	IF	CITATIONS
1	Integrative Clinical Genomics of Advanced Prostate Cancer. <i>Cell</i> , 2015, 161, 1215-1228.	28.9	2,660
2	DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2015, 373, 1697-1708.	27.0	1,796
3	Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. <i>Lancet, The</i> , 2016, 387, 1163-1177.	13.7	1,570
4	Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. <i>New England Journal of Medicine</i> , 2017, 377, 338-351.	27.0	1,315
5	Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. <i>Lancet, The</i> , 2018, 392, 2353-2366.	13.7	901
6	Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven. <i>Journal of Clinical Oncology</i> , 2008, 26, 4563-4571.	1.6	819
7	Prostate cancer. <i>Lancet, The</i> , 2016, 387, 70-82.	13.7	801
8	Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 3742-3748.	1.6	545
9	Characterization of <i>ERG</i> , <i>AR</i> and <i>PTEN</i> Gene Status in Circulating Tumor Cells from Patients with Castration-Resistant Prostate Cancer. <i>Cancer Research</i> , 2009, 69, 2912-2918.	0.9	518
10	Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. <i>European Urology</i> , 2018, 73, 178-211.	1.9	488
11	Duplication of the fusion of <i>TMPRSS2</i> to <i>ERG</i> sequences identifies fatal human prostate cancer. <i>Oncogene</i> , 2008, 27, 253-263.	5.9	400
12	Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate. <i>Journal of Clinical Oncology</i> , 2010, 28, 1489-1495.	1.6	370
13	Plasma <i>AR</i> and abiraterone-resistant prostate cancer. <i>Science Translational Medicine</i> , 2015, 7, 312re10.	12.4	366
14	Circulating Tumor Cell Biomarker Panel As an Individual-Level Surrogate for Survival in Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1348-1355.	1.6	343
15	Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). <i>Annals of Oncology</i> , 2013, 24, 1807-1812.	1.2	310
16	Tumor clone dynamics in lethal prostate cancer. <i>Science Translational Medicine</i> , 2014, 6, 254ra125.	12.4	298
17	Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. <i>Annals of Oncology</i> , 2015, 26, 1589-1604.	1.2	279
18	Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. <i>European Urology</i> , 2020, 77, 508-547.	1.9	278

#	ARTICLE	IF	CITATIONS
19	Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. <i>Annals of Oncology</i> , 2019, 30, 1992-2003.	1.2	262
20	Interactions of Abiraterone, Eplerenone, and Prednisolone with Wild-type and Mutant Androgen Receptor: A Rationale for Increasing Abiraterone Exposure or Combining with MDV3100. <i>Cancer Research</i> , 2012, 72, 2176-2182.	0.9	240
21	Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. <i>British Journal of Cancer</i> , 2010, 102, 678-684.	6.4	234
22	Clinical and Biochemical Consequences of CYP17A1 Inhibition with Abiraterone Given with and without Exogenous Glucocorticoids in Castrate Men with Advanced Prostate Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 507-516.	3.6	234
23	Phase 1 and Pharmacokinetic Study of Lexatumumab in Patients with Advanced Cancers. <i>Clinical Cancer Research</i> , 2007, 13, 6187-6194.	7.0	226
24	Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?. <i>Annals of Oncology</i> , 2012, 23, 2943-2947.	1.2	224
25	Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience. <i>Annals of Oncology</i> , 2009, 20, 27-33.	1.2	216
26	Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study. <i>Annals of Oncology</i> , 2017, 28, 1508-1516.	1.2	213
27	ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. <i>Annals of Oncology</i> , 2022, 33, 750-768.	1.2	204
28	Steroid Hormone Receptors in Prostate Cancer: A Hard Habit to Break?. <i>Cancer Cell</i> , 2009, 16, 458-462.	16.8	203
29	Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. <i>Annals of Oncology</i> , 2018, 29, 1235-1248.	1.2	196
30	PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate. <i>European Urology</i> , 2015, 67, 795-802.	1.9	195
31	Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer. <i>JAMA Oncology</i> , 2018, 4, 1179.	7.1	190
32	Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. <i>BJU International</i> , 2005, 96, 1241-1246.	2.5	186
33	Potential Applications for Circulating Tumor Cells Expressing the Insulin-Like Growth Factor-I Receptor. <i>Clinical Cancer Research</i> , 2007, 13, 3611-3616.	7.0	185
34	Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets. <i>Nature Genetics</i> , 2018, 50, 682-692.	21.4	182
35	All circulating EpCAM+CK+CD45- objects predict overall survival in castration-resistant prostate cancer. <i>Annals of Oncology</i> , 2010, 21, 1851-1857.	1.2	179
36	Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone. <i>European Journal of Cancer</i> , 2014, 50, 78-84.	2.8	178

#	ARTICLE	IF	CITATIONS
37	New Strategies in Metastatic Prostate Cancer: Targeting the Androgen Receptor Signaling Pathway. <i>Clinical Cancer Research</i> , 2011, 17, 1649-1657.	7.0	177
38	Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. <i>Lancet, The</i> , 2022, 399, 447-460.	13.7	173
39	Visceral Disease in Castration-resistant Prostate Cancer. <i>European Urology</i> , 2014, 65, 270-273.	1.9	172
40	Evolution of androgen receptor targeted therapy for advanced prostate cancer. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 365-376.	27.6	172
41	Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration. <i>Clinical Cancer Research</i> , 2015, 21, 4586-4596.	7.0	171
42	Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC). <i>Annals of Oncology</i> , 2010, 21, 109-113.	1.2	157
43	Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer. <i>JAMA Oncology</i> , 2016, 2, 348.	7.1	155
44	Antitumor Activity with CYP17 Blockade Indicates That Castration-Resistant Prostate Cancer Frequently Remains Hormone Driven. <i>Cancer Research</i> , 2009, 69, 4937-4940.	0.9	152
45	Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects. <i>Oncogene</i> , 2015, 34, 1745-1757.	5.9	147
46	Abiraterone in "High" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer. <i>European Urology</i> , 2019, 76, 719-728.	1.9	142
47	Sequencing of agents in castration-resistant prostate cancer. <i>Lancet Oncology, The</i> , 2015, 16, e279-e292.	10.7	141
48	Multi-Purpose Utility of Circulating Plasma DNA Testing in Patients with Advanced Cancers. <i>PLoS ONE</i> , 2012, 7, e47020.	2.5	136
49	Update on tubulin-binding agents. <i>Pathologie Et Biologie</i> , 2006, 54, 72-84.	2.2	134
50	Complex patterns of ETS gene alteration arise during cancer development in the human prostate. <i>Oncogene</i> , 2008, 27, 1993-2003.	5.9	133
51	Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment. <i>Journal of Clinical Oncology</i> , 2018, 36, 2639-2646.	1.6	131
52	Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio. <i>Cancer</i> , 2014, 120, 3346-3352.	4.1	128
53	Activity of Cabazitaxel in Castration-resistant Prostate Cancer Progressing After Docetaxel and Next-generation Endocrine Agents. <i>European Urology</i> , 2014, 66, 459-465.	1.9	128
54	Open-Label Phase II Study Evaluating the Efficacy and Safety of Two Doses of Pertuzumab in Castrate Chemotherapy-Naive Patients With Hormone-Refractory Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 257-262.	1.6	127

#	ARTICLE	IF	CITATIONS
55	Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study. <i>Lancet Oncology</i> , The, 2012, 13, 1114-1124.	10.7	125
56	Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone. <i>British Journal of Cancer</i> , 2015, 112, 1717-1724.	6.4	112
57	Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. <i>European Urology</i> , 2018, 73, 715-723.	1.9	105
58	Utilizing circulating tumor cells: challenges and pitfalls. <i>Current Opinion in Genetics and Development</i> , 2011, 21, 50-58.	3.3	101
59	Prostate epithelial stem cells. <i>Cell Proliferation</i> , 2005, 38, 363-374.	5.3	99
60	Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer. <i>British Journal of Cancer</i> , 2008, 99, 314-320.	6.4	98
61	CYP17 inhibition as a hormonal strategy for prostate cancer. <i>Nature Reviews Urology</i> , 2008, 5, 610-620.	1.4	96
62	Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer. <i>Annals of Oncology</i> , 2014, 25, 657-662.	1.2	94
63	Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 556-569.	10.7	90
64	Targeting CYP17: established and novel approaches in prostate cancer. <i>Current Opinion in Pharmacology</i> , 2008, 8, 449-457.	3.5	87
65	Improved Survival in a Cohort of Trial Participants with Metastatic Castration-resistant Prostate Cancer Demonstrates the Need for Updated Prognostic Nomograms. <i>European Urology</i> , 2013, 64, 300-306.	1.9	85
66	The Association of PI3 Kinase Signaling and Chemoresistance in Advanced Ovarian Cancer. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 1609-1617.	4.1	82
67	Circulating Tumor Cells Count and Morphological Features in Breast, Colorectal and Prostate Cancer. <i>PLoS ONE</i> , 2013, 8, e67148.	2.5	82
68	Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer. <i>JAMA Oncology</i> , 2021, 7, 544.	7.1	82
69	Molecular Pathways: Inhibiting Steroid Biosynthesis in Prostate Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 3353-3359.	7.0	80
70	Second-Generation HSP90 Inhibitor Onalespib Blocks mRNA Splicing of Androgen Receptor Variant 7 in Prostate Cancer Cells. <i>Cancer Research</i> , 2016, 76, 2731-2742.	0.9	79
71	First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer. <i>British Journal of Cancer</i> , 2013, 109, 2579-2586.	6.4	78
72	PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients. <i>British Journal of Cancer</i> , 2015, 113, 1225-1233.	6.4	76

#	ARTICLE	IF	CITATIONS
73	Improving the outcome of patients with castration-resistant prostate cancer through rational drug development. <i>British Journal of Cancer</i> , 2006, 95, 767-774.	6.4	72
74	Circulating <i>AR</i> copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer. <i>Oncotarget</i> , 2016, 7, 37839-37845.	1.8	69
75	Genome-wide plasma DNA methylation features of metastatic prostate cancer. <i>Journal of Clinical Investigation</i> , 2020, 130, 1991-2000.	8.2	68
76	Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer. <i>JAMA Oncology</i> , 2021, 7, 555.	7.1	66
77	A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2007, 97, 1338-1343.	6.4	65
78	Expression profiling of CD133 <sup>+</sup> and CD133 <sup>+</sup> epithelial cells from human prostate. <i>Prostate</i> , 2008, 68, 1007-1024.	2.3	64
79	Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2019, 75, 368-373.	1.9	64
80	Hsp-27 expression at diagnosis predicts poor clinical outcome in prostate cancer independent of ETS-gene rearrangement. <i>British Journal of Cancer</i> , 2009, 101, 1137-1144.	6.4	62
81	Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer. <i>Annals of Oncology</i> , 2013, 24, 1416-1418.	1.2	62
82	Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study. <i>Lancet Oncology</i> , The, 2021, 22, 1541-1559.	10.7	60
83	Preclinical Evaluation of Imaging Biomarkers for Prostate Cancer Bone Metastasis and Response to Cabozantinib. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju033.	6.3	59
84	Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents. <i>British Journal of Cancer</i> , 2015, 112, 1166-1174.	6.4	59
85	Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2016, 70, 724-731.	1.9	59
86	Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse. <i>Nature Communications</i> , 2021, 12, 5307.	12.8	58
87	Combining Enzalutamide with Abiraterone, Prednisone, and Androgen Deprivation Therapy in the STAMPEDE Trial. <i>European Urology</i> , 2014, 66, 799-802.	1.9	56
88	The CT flare response of metastatic bone disease in prostate cancer. <i>Acta Radiologica</i> , 2011, 52, 557-561.	1.1	55
89	Integration of <i>ERG</i> gene mapping and gene expression profiling identifies distinct categories of human prostate cancer. <i>BJU International</i> , 2009, 103, 1256-1269.	2.5	54
90	Phenotypic diversity of circulating tumour cells in patients with metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2017, 120, E30-E44.	2.5	54

#	ARTICLE	IF	CITATIONS
91	Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 1530-1541.	1.6	54
92	The Role of Abiraterone Acetate in the Management of Prostate Cancer: A Critical Analysis of the Literature. <i>European Urology</i> , 2011, 60, 270-278.	1.9	53
93	Translating Scientific Advancement into Clinical Benefit for Castration-Resistant Prostate Cancer Patients. <i>Clinical Cancer Research</i> , 2011, 17, 3867-3875.	7.0	53
94	Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone. <i>British Journal of Cancer</i> , 2014, 111, 2248-2253.	6.4	52
95	Improvements in Radiographic Progression-Free Survival Stratified by <i>ERG</i> Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate. <i>Clinical Cancer Research</i> , 2015, 21, 1621-1627.	7.0	51
96	Assessment of the Safety of Glucocorticoid Regimens in Combination With Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer. <i>JAMA Oncology</i> , 2019, 5, 1159.	7.1	50
97	Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer. <i>Modern Pathology</i> , 2012, 25, 902-910.	5.5	48
98	Intratumoural evolutionary landscape of high-risk prostate cancer: the PROGENY study of genomic and immune parameters. <i>Annals of Oncology</i> , 2017, 28, 2472-2480.	1.2	45
99	Drivers of AR indifferent anti-androgen resistance in prostate cancer cells. <i>Scientific Reports</i> , 2019, 9, 13786.	3.3	44
100	Making sense of antisense. <i>European Journal of Cancer</i> , 2005, 41, 2812-2818.	2.8	43
101	Transcriptional profiling of primary prostate tumor in metastatic hormone-sensitive prostate cancer and association with clinical outcomes: correlative analysis of the E3805 CHAARTED trial. <i>Annals of Oncology</i> , 2021, 32, 1157-1166.	1.2	43
102	Unbiased and Automated Identification of a Circulating Tumour Cell Definition That Associates with Overall Survival. <i>PLoS ONE</i> , 2011, 6, e27419.	2.5	42
103	Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 825-836.	1.6	40
104	Circulating tumor DNA in advanced prostate cancer: transitioning from discovery to a clinically implemented test. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 195-205.	3.9	39
105	Strategies for managing ACTH dependent mineralocorticoid excess induced by abiraterone. <i>Cancer Treatment Reviews</i> , 2013, 39, 966-973.	7.7	37
106	Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial. <i>PLoS Medicine</i> , 2022, 19, e1003998.	8.4	35
107	Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancer. <i>British Journal of Cancer</i> , 2013, 109, 325-331.	6.4	34
108	Validation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trail. <i>British Journal of Cancer</i> , 2014, 111, 828-836.	6.4	34

#	ARTICLE	IF	CITATIONS
109	Abiraterone Acetate Is Well Tolerated Without Concomitant Use of Corticosteroids. <i>Journal of Clinical Oncology</i> , 2010, 28, e560-e561.	1.6	33
110	AR aberrations and resistance to abiraterone or enzalutamide. <i>Nature Reviews Urology</i> , 2016, 13, 697-698.	3.8	33
111	A First-in-Man Phase I and Pharmacokinetic Study on CHR-2797 (Tosedostat), an Inhibitor of M1 Aminopeptidases, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2009, 15, 4978-4985.	7.0	31
112	Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 485-493.	1.9	30
113	Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials. <i>Clinical Cancer Research</i> , 2011, 17, 5188-5196.	7.0	29
114	Putting the brakes on continued androgen receptor signaling in castration-resistant prostate cancer. <i>Molecular and Cellular Endocrinology</i> , 2012, 360, 68-75.	3.2	29
115	Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH) Tj ETQq1 1 06784314 rgBT /Over	2.8	29
116	Plasma AR status and cabazitaxel in heavily treated metastatic castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2019, 116, 158-168.	2.8	29
117	Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476). <i>International Journal of Cancer</i> , 2022, 151, 422-434.	5.1	29
118	Consensus Statement on Circulating Biomarkers for Advanced Prostate Cancer. <i>European Urology Oncology</i> , 2018, 1, 151-159.	5.4	28
119	Sarcomatoid carcinoma of the prostate: <i>in situ</i> fluorescence <i>in situ</i> hybridization confirms epithelial origin. <i>Histopathology</i> , 2015, 66, 898-901.	2.9	26
120	Blood-based liquid biopsies for prostate cancer: clinical opportunities and challenges. <i>British Journal of Cancer</i> , 2022, 127, 1394-1402.	6.4	25
121	Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone. <i>Annals of Oncology</i> , 2017, 28, 90-95.	1.2	24
122	Plasma tumour DNA as an early indicator of treatment response in metastatic castration-resistant prostate cancer. <i>British Journal of Cancer</i> , 2020, 123, 982-987.	6.4	22
123	Genomic Profiles of De Novo High- and Low-Volume Metastatic Prostate Cancer: Results From a 2-Stage Feasibility and Prevalence Study in the STAMPEDE Trial. <i>JCO Precision Oncology</i> , 2020, 4, 882-897.	3.0	22
124	Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trial. <i>Annals of Oncology</i> , 2021, 32, 726-735.	1.2	22
125	A phase I study of intravenous TZT-1027 administered on day 1 and day 8 of a three-weekly cycle in combination with carboplatin given on day 1 alone in patients with advanced solid tumours. <i>Annals of Oncology</i> , 2006, 17, 1313-1319.	1.2	21
126	Hormone-sensitive prostate cancer: a case of ETS gene fusion heterogeneity. <i>Journal of Clinical Pathology</i> , 2009, 62, 373-376.	2.0	21

#	ARTICLE	IF	CITATIONS
127	External Validation of a Prognostic Model Predicting Overall Survival in Metastatic Castrate-resistant Prostate Cancer Patients Treated with Abiraterone. <i>European Urology</i> , 2014, 66, 8-11.	1.9	21
128	Plasma androgen receptor and serum chromogranin A in advanced prostate cancer. <i>Scientific Reports</i> , 2018, 8, 15442.	3.3	21
129	CD38 in Advanced Prostate Cancers. <i>European Urology</i> , 2021, 79, 736-746.	1.9	21
130	Anti-androgen monotherapy for metastatic prostate cancer. <i>Lancet Oncology</i> , The, 2014, 15, 543-544.	10.7	20
131	Emerging Molecular Biomarkers in Advanced Prostate Cancer: Translation to the Clinic. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, 131-141.	3.8	19
132	Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness. <i>European Urology Oncology</i> , 2018, 1, 449-458.	5.4	19
133	Reporting the Capture Efficiency of a Filter-Based Microdevice: A CTC Is Not a CTC Unless It Is CD45 Negative Letter: Figure 1.. <i>Clinical Cancer Research</i> , 2011, 17, 3048-3049.	7.0	18
134	Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer. <i>British Journal of Cancer</i> , 2013, 109, 1079-1084.	6.4	18
135	An open-label, multicenter, phase Ib study investigating the effect of apalutamide on ventricular repolarization in men with castration-resistant prostate cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 457-468.	2.3	18
136	Studies of <i>TMPRSS2-ERG</i> Gene Fusions in Diagnostic Trans-Rectal Prostate Biopsies. <i>Clinical Cancer Research</i> , 2010, 16, 1340-1340.	7.0	17
137	Definitions of disease burden across the spectrum of metastatic castration-sensitive prostate cancer: comparison by disease outcomes and genomics. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 713-719.	3.9	17
138	Redefining the therapeutic landscape for CRPC. <i>Nature Reviews Urology</i> , 2012, 9, 63-64.	3.8	16
139	Plasma DNA Analysis in Prostate Cancer: Opportunities for Improving Clinical Management. <i>Clinical Chemistry</i> , 2019, 65, 100-107.	3.2	16
140	Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. <i>Annals of Oncology</i> , 2019, 30, e3.	1.2	16
141	Emerging Molecular Biomarkers in Advanced Prostate Cancer: Translation to the Clinic. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 36, 131-141.	3.8	16
142	Beyond Hormone Therapy for Prostate Cancer with PARP inhibitors. <i>Cancer Cell</i> , 2011, 19, 573-574.	16.8	15
143	Visualizing whole-body treatment response heterogeneity using multi-parametric magnetic resonance imaging. <i>Journal of Algorithms and Computational Technology</i> , 2016, 10, 290-301.	0.7	15
144	Circulating Tumour DNA in Muscle-Invasive Bladder Cancer. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2568.	4.1	15

#	ARTICLE	IF	CITATIONS
145	Plasma Androgen Receptor Copy Number Status at Emergence of Metastatic Castration-Resistant Prostate Cancer: A Pooled Multicohort Analysis. <i>JCO Precision Oncology</i> , 2019, 3, 1-13.	3.0	15
146	The development of abiraterone acetate for castration-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 289-294.	1.6	14
147	Effects of abiraterone acetate plus prednisone/prednisolone in high and low risk metastatic hormone sensitive prostate cancer. <i>Annals of Oncology</i> , 2018, 29, viii722.	1.2	14
148	A phase I study of BIBF 1120, an orally active triple angiokinase inhibitor (VEGFR, PDGFR, FGFR) given continuously to patients with advanced solid tumours, incorporating dynamic contrast enhanced magnetic resonance imaging (DCE-MRI). <i>Journal of Clinical Oncology</i> , 2006, 24, 3015-3015.	1.6	14
149	Targeting extra-gonadal androgens in castration-resistant prostate cancer. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2015, 145, 157-163.	2.5	13
150	Circulating androgen receptor gene amplification and resistance to 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: results of a Phase 2 trial. <i>British Journal of Cancer</i> , 2021, 125, 1226-1232.	6.4	13
151	Improved Therapeutic Targeting of the Androgen Receptor: Rational Drug Design Improves Survival in Castration-Resistant Prostate Cancer. <i>Current Drug Targets</i> , 2013, 14, 408-419.	2.1	13
152	Dissecting prostate carcinogenesis through ETS gene rearrangement studies: implications for anticancer drug development. <i>Journal of Clinical Pathology</i> , 2008, 61, 891-896.	2.0	12
153	Treatment-induced changes in the androgen receptor axis: Liquid biopsies as diagnostic/prognostic tools for prostate cancer. <i>Molecular and Cellular Endocrinology</i> , 2018, 462, 56-63.	3.2	12
154	Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findings. <i>European Journal of Cancer</i> , 2022, 160, 24-60.	2.8	12
155	Advances in the management of high-risk localised and metastatic prostate cancer. <i>BJU International</i> , 2012, 109, 8-13.	2.5	11
156	Novel Strategies to Test Biological Hypotheses in Early Drug Development for Advanced Prostate Cancer. <i>Clinical Chemistry</i> , 2013, 59, 75-84.	3.2	11
157	Prioritizing precision medicine for prostate cancer. <i>Annals of Oncology</i> , 2015, 26, 1041-1042.	1.2	11
158	Pharmacokinetics, Safety, and Antitumor Effect of Apalutamide with Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: Phase Ib Study. <i>Clinical Cancer Research</i> , 2020, 26, 3517-3524.	7.0	11
159	Prostate Cancer Foundation Hormone-Sensitive Prostate Cancer Biomarker Working Group Meeting Summary. <i>Urology</i> , 2021, 155, 165-171.	1.0	11
160	PSA as an intermediate end point in clinical trials. <i>Nature Reviews Urology</i> , 2009, 6, 473-475.	3.8	10
161	Identification of single nucleotide variants using position-specific error estimation in deep sequencing data. <i>BMC Medical Genomics</i> , 2019, 12, 115.	1.5	10
162	A novel, spontaneously immortalized, human prostate cancer cell line, Bob, offers a unique model for pre-clinical prostate cancer studies. <i>Prostate</i> , 2009, 69, 1507-1520.	2.3	9

#	ARTICLE	IF	CITATIONS
163	The Automated Bone Scan Index as a Predictor of Response to Prostate Radiotherapy in Men with Newly Diagnosed Metastatic Prostate Cancer: An Exploratory Analysis of STAMPEDEâ€™s â€œM1   RT Comparisonâ€. <i>European Urology Oncology</i> , 2020, 3, 412-419.	5.4	9
164	A phase IV, randomized, double-blind, placebo (PBO)-controlled study of continued enzalutamide (ENZA) post prostate-specific antigen (PSA) progression in men with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 5004-5004.	1.6	9
165	Multimodal Approach to Outcome Prediction in Metastatic Castration-Resistant Prostate Cancer by Integrating Functional Imaging and Plasma DNA Analysis. <i>JCO Precision Oncology</i> , 2019, 3, 1-13.	3.0	8
166	Progressive computed tomography (CT) appearances preceding malignant spinal cord compression (MSCC) in men with castration-resistant prostate cancer. <i>Clinical Radiology</i> , 2015, 70, 359-365.	1.1	7
167	Plasma DNA and Metastatic Castration-Resistant Prostate Cancer: The Odyssey to a Clinical Biomarker Test. <i>Cancer Discovery</i> , 2018, 8, 392-394.	9.4	7
168	ABEMUS: platform-specific and data-informed detection of somatic SNVs in cfDNA. <i>Bioinformatics</i> , 2020, 36, 2665-2674.	4.1	7
169	Circulating Androgen Receptor for Prognosis and Treatment Selection in Prostate Cancer. <i>European Urology Oncology</i> , 2021, 4, 740-744.	5.4	7
170	LBA4 Abiraterone acetate plus prednisolone (AAP) with or without enzalutamide (ENZ) added to androgen deprivation therapy (ADT) compared to ADT alone for men with high-risk non-metastatic (M0) prostate cancer (PCa): Combined analysis from two comparisons in the STAMPEDE platform protocol. <i>Annals of Oncology</i> , 2021, 32, S1298.	1.2	7
171	Identifying prognostic signatures in the blood of ovarian cancer patients. <i>Gynecologic Oncology</i> , 2013, 128, 1-2.	1.4	6
172	Androgen receptor (AR) aberrations in patients (Pts) with metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) plus androgen deprivation therapy (ADT) in TITAN. <i>Annals of Oncology</i> , 2019, 30, v347-v348.	1.2	6
173	Blood Biomarker Landscape in Patients with High-risk Nonmetastatic Castration-Resistant Prostate Cancer Treated with Apalutamide and Androgen-Deprivation Therapy as They Progress to Metastatic Disease. <i>Clinical Cancer Research</i> , 2021, 27, 4539-4548.	7.0	6
174	The identification of chromosomal translocation, t(4;6)(q22;q15), in prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2010, 13, 117-125.	3.9	5
175	A step toward functionally characterized prostate cancer molecular subtypes. <i>Nature Medicine</i> , 2013, 19, 966-967.	30.7	5
176	Phase I Study of Nintedanib Incorporating Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Patients With Advanced Solid Tumors. <i>Oncologist</i> , 2015, 20, 368-369.	3.7	5
177	Should Patients with High-risk Localised or Locally Advanced Prostate Cancer Receive Abiraterone Acetate in Addition to Androgen Deprivation Therapy? Update on a Planned Analysis of the STAMPEDE Trial. <i>European Urology</i> , 2021, 80, 522-523.	1.9	5
178	Phase Ib study of apalutamide (APA) with abiraterone acetate (AA) and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Update on safety and efficacy.. <i>Journal of Clinical Oncology</i> , 2017, 35, 173-173.	1.6	5
179	Diagnostic Gleason score and castration-resistant prostate cancer. <i>Annals of Oncology</i> , 2016, 27, 962-964.	1.2	4
180	Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from â€œcastration-resistantâ€ prostate cancer. <i>Annals of Oncology</i> , 2017, 28, 1692-1694.	1.2	4

#	ARTICLE	IF	CITATIONS
181	Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: A multicenter biomarker study. <i>European Journal of Cancer</i> , 2021, 152, 49-59.	2.8	4
182	Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data. <i>PLoS ONE</i> , 2022, 17, e0269192.	2.5	4
183	Cabazitaxel—a key therapeutic option in prostate cancer. <i>Nature Reviews Urology</i> , 2015, 12, 312-313.	3.8	3
184	Prostate cancers that $\Delta$ Wnt <sup>TM</sup> respond to abiraterone. <i>Annals of Oncology</i> , 2018, 29, 290-292.	1.2	3
185	Abiraterone in Patients with Metastatic Castration-Resistant Prostate Cancer Progressing after Docetaxel and MDV3100: A Multicentre Study. <i>Annals of Oncology</i> , 2012, 23, ix304-ix305.	1.2	2
186	Prolonged urinary and bowel symptom control in men with non-metastatic castration-resistant prostate cancer (nmCRPC) treated with enzalutamide: Results from the PROSPER study. <i>Annals of Oncology</i> , 2018, 29, viii278-viii279.	1.2	2
187	A phase III randomized, placebo-controlled, double-blind study of niraparib plus abiraterone acetate and prednisone versus abiraterone acetate and prednisone in patients with metastatic prostate cancer (NCT03748641). <i>Annals of Oncology</i> , 2019, 30, v354.	1.2	2
188	692TiP BRCA2men: An international, multicentre, observational and ambispective study to validate the predictive value of germline BRCA2 mutations for selecting the first-line of treatment in metastatic castration-resistant prostate cancer (mCRPC). <i>Annals of Oncology</i> , 2020, 31, S547-S548.	1.2	2
189	The ReIMAGINE prostate cancer risk study protocol: A prospective cohort study in men with a suspicion of prostate cancer who are referred onto an MRI-based diagnostic pathway with donation of tissue, blood and urine for biomarker analyses.. <i>PLoS ONE</i> , 2022, 17, e0259672.	2.5	2
190	Reply: $\Delta$ Comment on Anti-tumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer <sup>TM</sup> . <i>British Journal of Cancer</i> , 2014, 110, 267-268.	6.4	1
191	Upfront Docetaxel in the Post-STAMPEDE World: Lessons from an Early Evaluation of Non-trial Usage in Hormone-Sensitive Prostate Cancer. <i>Clinical Oncology</i> , 2017, 29, e174-e175.	1.4	1
192	Overall survival (OS) implications for patients with mCRPC through coverage and adoption of nuclear AR-V7 testing by healthcare systems. <i>Annals of Oncology</i> , 2018, 29, viii296-viii297.	1.2	1
193	634P Impact of metastatic lymph node burden on survival in patients with mHSPC from the "docetaxel comparison" of the STAMPEDE trial. <i>Annals of Oncology</i> , 2020, 31, S522-S523.	1.2	1
194	A randomized trial of abiraterone acetate (AA) administered with 1 of 4 glucocorticoid (GC) regimens in metastatic castration-resistant prostate cancer (mCRPC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2016, 34, 261-261.	1.6	1
195	Association of androgen receptor (AR) status in plasma DNA with outcome on enzalutamide (enza) or abiraterone (abi) for castration resistant prostate cancer (CRPC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 5060-5060.	1.6	1
196	Management Strategies for Hormone-Refractory Prostate Cancer. <i>American Journal of Cancer</i> , 2006, 5, 163-169.	0.4	0
197	Novel biomarker approaches for improving therapeutic strategies in metastatic breast cancer. , 2011, , 165-181.		0
198	Derivation and Validation of Blood mRNA Expression Signatures to Stratify Castration Resistant Prostate Cancer Patients and Predict Poor Outcome. <i>Annals of Oncology</i> , 2012, 23, ix15.	1.2	0

#	ARTICLE	IF	CITATIONS
199	New horizons for prostate cancer: part 2. Trends in Urology & Men's Health, 2013, 4, 13-16.	0.4	0
200	New horizons for prostate cancer: part 1. Trends in Urology & Men's Health, 2013, 4, 38-40.	0.4	0
201	Reply to: Enzalutamide after failure of docetaxel and abiraterone in metastatic castrate resistant prostate cancer. European Journal of Cancer, 2014, 50, 1042-1043.	2.8	0
202	Phase II study of prednisone-dexamethasone switch in metastatic castration resistant prostate cancer (mCRPC) patients treated with abiraterone and prednisone (AA+P). Annals of Oncology, 2017, 28, v276.	1.2	0
203	Implementing molecular characterisation of prostate cancer tissue from patients recruited to the multi-centre STAMPEDE trial: The STRATOSPHERE consortium. Annals of Oncology, 2018, 29, vi10.	1.2	0
204	Drivers and therapeutic vulnerabilities in AR indifferent anti-androgen resistant prostate cancer cells. European Urology Supplements, 2019, 18, e3104.	0.1	0
205	589P Dynamics of peripheral blood immune profiling associated with tumour progression in metastatic castration resistant prostate cancer (mCRPC). Annals of Oncology, 2021, 32, S637-S638.	1.2	0
206	584P Health-related quality of life (HRQoL) in ACIS: A phase III trial of apalutamide with abiraterone acetate and prednisone (APA + AAP) vs AAP in metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology, 2021, 32, S634.	1.2	0
207	583P Baseline plasma tumour DNA (ptDNA) correlates with PSA kinetics in metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone or enzalutamide. Annals of Oncology, 2021, 32, S633.	1.2	0
208	650TiP PARADIGM: Plasma analysis for response assessment and to direct the management of metastatic prostate cancer (mPCa). Annals of Oncology, 2021, 32, S677.	1.2	0
209	Emerging Prognostic Groups Across the Spectrum of Metastatic Castration-Sensitive Prostate Cancer: Disease Outcomes and Genomics. International Journal of Radiation Oncology Biology Physics, 2021, 111, e294-e295.	0.8	0
210	A phase 1 dose finding study of CHR-2797, an inhibitor of M1 aminopeptidases, in patients with advanced solid tumours. Journal of Clinical Oncology, 2006, 24, 3053-3053.	1.6	0
211	Circulating tumor cells expressing the insulin growth factor-1 receptor (IGF-1R): Method of detection, incidence and potential applications. Journal of Clinical Oncology, 2007, 25, 3507-3507.	1.6	0
212	Improved Survival in Patients with Metastatic Castration Resistant Prostate Cancer (MCRPC) Treated on Clinical Trials. Annals of Oncology, 2012, 23, ix298.	1.2	0
213	PSA levels after dexamethasone withdrawal (DW) in castration resistant prostate cancer (CRPC).. Journal of Clinical Oncology, 2016, 34, 278-278.	1.6	0
214	Loco-regional treatment (LRT) for M1 at diagnosis prostate cancer (PCa) patients (pts) and impact on overall survival (OS): A retrospective analysis.. Journal of Clinical Oncology, 2016, 34, 280-280.	1.6	0
215	Validation of a population pharmacokinetic (PPK) model for onapristone (ONA) in patients (pts) with cancer: Analysis of 2 clinical trials.. Journal of Clinical Oncology, 2016, 34, e14099-e14099.	1.6	0
216	Circulating <i>AR</i> copy number and outcome to enzalutamide in patients with metastatic castration-resistant prostate cancer after docetaxel.. Journal of Clinical Oncology, 2016, 34, e16583-e16583.	1.6	0

#	ARTICLE	IF	CITATIONS
217	Clinical and radiological characteristics of metastatic prostate cancer (mPCa) patients (pts) with liver metastases (LM) and association with overall survival (OS).. Journal of Clinical Oncology, 2016, 34, 5043-5043.	1.6	0
218	Circulating androgen receptor and serum chromogranin A in castration-resistant prostate cancers (CRPC) patients treated with abiraterone and enzalutamide.. Journal of Clinical Oncology, 2017, 35, 160-160.	1.6	0
219	Phase 1-2 study of progesterone receptor (PR) inhibition with extended-release (ER) onapristone (ONA) alone or in combination with abiraterone (AA) in patients (pts) with castration-resistant prostate cancer (CRPC) incorporating plasma DNA analysis to define androgen receptor (AR) status.. Journal of Clinical Oncology, 2017, 35, 5071-5071.	1.6	0
220	Association of androgen receptor (AR) gene status in plasma DNA with outcome on enzalutamide in chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC): Exploratory results from the PREMIERE trial" On behalf of SOGUG.. Journal of Clinical Oncology, 2017, 35, 5016-5016.	1.6	0